Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04016805 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
A Phase 2 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04016805 is a Phase 2 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT04016805, a Phase 2 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in participants with Chronic Lymphocytic Leukemia (CLL), who are currently on treatment with ibrutinib, alacabrutinib or venetoclax.
Interventions
- DRUG Venetoclax
- DRUG Ublituximab
- DRUG Ibrutinib
- DRUG Umbralisib
- DRUG Acalabrutinib Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2022-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04016805
The ClinicalTrials.gov registry entry for NCT04016805 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Venetoclax is the first listed.
NCT04016805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04016805 about?
NCT04016805 is a clinical study titled "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax". Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in participants with Chronic Lymphocytic Leukemia (CLL), who are currently on treatment with ibrutinib, alacabrutinib or venetoclax.
What is the current status of trial NCT04016805?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2019-08-05. Estimated completion is 2022-05-22.
What interventions are being tested in trial NCT04016805?
The interventions under investigation include: Venetoclax (DRUG), Ublituximab (DRUG), Ibrutinib (DRUG), Umbralisib (DRUG), Acalabrutinib Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT04016805?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.